

# Association of allergic rhinitis with obstructive sleep apnea

## A meta-analysis

Yuan Cao, MD<sup>a</sup>, Shuang Wu, MM<sup>b</sup>, Liyu Zhang, MM<sup>c</sup>, Ying Yang, PhD<sup>c</sup>, Sancheng Cao, BS<sup>b</sup>, Qiao Li, PhD<sup>b,c,\*</sup>

### Abstract

**Background:** The co-existence of allergic rhinitis (AR) and obstructive sleep apnea (OSA) is a common phenomenon in clinical practice. AR has long been considered a risk factor for OSA. However, the relationship is not completely clear. Therefore, we conducted a meta-analysis to evaluate the prevalence of AR in sleep-disordered breathing (SDB) /OSA and their relationship.

**Methods:** A comprehensive literature search was performed in PubMed/Medline, Google Scholar, Wiley Online Library, EMBASE, and Web of Science. Data were analyzed and pooled to estimate effect size (ES) /odds ratio (OR) with 95% confidence intervals (95% CI). Heterogeneity was quantified and evaluated by chi-squared-based Q-test and I<sup>2</sup> test, with  $P < .05$  and  $I^2 > 50\%$  indicating evidence of heterogeneity.

**Results:** 44 studies contained 6086 participants were included in this meta-analysis. For adults, the prevalence of AR was 22.8 (95% CI, 15.0–30.6) % in SDB and 35.2 (95% CI, 25.6–44.7) % in OSA. In children with SDB and OSA, the prevalence of AR was 40.8 (95% CI, 24.3–57.2) %, and 45.2 (95% CI, 25.4–65.0) % respectively. The odds ratios of prevalence of the SDB pediatric patients with AR was 2.12 (95%CI, 1.75, 2.57;  $P < .0001$ ) times higher than that of non-SDB pediatric patients. There were no significant differences between OSA adults with or without AR in BMI (Body Mass Index), neck circumference, apnea hypopnea index (AHI) and Epworth sleep scale score (ESS).

**Conclusion:** The prevalence of AR in OSA/SDB is considerably high and children with SDB suffering from a higher incidence of AR than non-SDB. OSA adults accompanied with AR do not have any influences on sleep parameters.

**Abbreviations:** AH = adenotonsillar hypertrophy, AHI = apnea hypopnea index, AR = allergic rhinitis, BMI = body mass index, CI = confidence intervals, CPAP = continuous positive airway pressure, cysLTs = cysteinyl leukotriene, ES = estimate effect size, ESS = Epworth Sleep Scale Score, IgE = immunoglobulin E, IL-1 $\beta$  = interleukin-1 $\beta$ , IL-4 = interleukin-4, INCS = intranasal corticosteroids, OR = odds ratio, OSA = obstructive sleep apnea, PRISMA = Preferred Reporting Items for Systematic Reviews and Meta-analysis, PSG = polysomnography, SDB = sleep-disordered breathing, Th2 = T helper 2 lymphocyte.

**Keywords:** allergic rhinitis, apnea hypopnea index, body mass index, Epworth Sleep Scale score, meta-analysis, obstructive sleep apnea

### 1. Introduction

Obstructive sleep apnea (OSA) is the most common sleep-disordered breathing (SDB). The prevalence of OSA in healthy children and adults was as high as 1% to 5% and 3.5% to

20.4%, respectively, and it was even higher for SDB.<sup>[1–4]</sup> OSA is characterized by prolonged partial upper airway obstruction and/or intermittent complete obstruction. It disrupts normal ventilation and patterns during sleep.<sup>[1]</sup> Moreover, these breathing

Editor: Stefano Omboni.

For this type of study formal consent is not required.

Ethical approval and informed consent were not suitable for this study.

Funding: This work was funded by Shanxi Key Science and Technology of Social Development Program 2016SF-036, Xi'an Science and Technology program SF1510 (4).

Conflict of interest: All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers' bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent/licensing arrangements), or nonfinancial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.

Supplemental Digital Content is available for this article.

<sup>a</sup> Department of Pulmonary and Critical Care Medicine, The Second Affiliated Hospital of Medical College, Xi'an Jiaotong University, <sup>b</sup> Clinical Laboratory, <sup>c</sup> Institute of Pediatric Diseases, The Affiliated Children Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.

\* Correspondence: Qiao Li, Clinical Laboratory, The Affiliated Children Hospital of Xi'an Jiaotong University, No. 69, Xijuyuan Lane, Lianhu District, Xi'an 710003, Shaanxi, China (e-mail: liqiao@csu.edu.cn).

Copyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc.

This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Medicine (2018) 97:51(e13783)

Received: 14 May 2018 / Accepted: 28 November 2018

<http://dx.doi.org/10.1097/MD.0000000000013783>

disorders may increase the risks of complications of cardiovascular, neurocognitive, and metabolic morbidities.<sup>[5]</sup> Allergic diseases, allergic rhinitis (AR), asthma, and eczema are common among individuals. AR is a very common disease that affects 10% to 40% of the global population.<sup>[6]</sup> With the increasing exposure to allergens and pollutants, the prevalence of AR has increased over the past few decades.<sup>[7]</sup> Since it usually leads to nasal obstruction and increased upper airway resistance, AR has long been recognized as a risk factor of OSA in previous studies.<sup>[8–10]</sup> Some articles have reviewed the association between AR and SDB in children. However, no meta-analysis was obtained from databases. Therefore, in view of this scenario, we conducted a meta-analysis to explore and summarize the prevalence and association between OSA and AR in order to gain a deeper insight of these 2 diseases.

## 2. Materials and methods

We performed this meta-analysis in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement.<sup>[11]</sup>

### 2.1. Literature search

In accordance with the PRISMA guidelines, we identified relevant research articles through a systematic review of scientific databases (PubMed /Medline, Google Scholar, Wiley Online Library, Embase, and Web of Science). The MeSH and keywords used in different logical combinations and phrases were: allergic rhinitis, allergic rhino conjunctivitis, hay fever, nasal allergy, OSA, apnea, hypopnea, Epworth Sleepiness Scale (ESS), apnea-hypopnea index (AHI), SDB, sleep-associated breathing disorder, sleep-related disordered breathing, snoring. The search encompassed original research papers published by July 1, 2017 in online journals in English language.

### 2.2. Inclusion and exclusion criteria

Inclusion criterion was clinical or epidemiological studies which examined the relationship between AR and sleep disorders and reported the prevalence of AR in OSA or SDB patients. Studies were excluded from the meta-analysis if reported only the sleep quality measures other than OSA or SDB, or provided qualitative information only. Other studies that were excluded include review article, conference abstract, article not published in English, animal study, case report, article with no abstract/full text available.

### 2.3. Data extraction

The following data were extracted from each eligible study: participants' demographic and clinical characteristics, the prevalence of AR in OSA (diagnosed with sleep studies according to guidelines),<sup>[1,12]</sup> and SDB (one or more abnormal/difficulty breathing during sleep and/or gas exchange patterns during sleep including habitual snoring 3 or more times per week) patients, body mass index (BMI), neck circumference, AHI and ESS score, and other relevant information were obtained from the selected research articles of the respective studies and organized on data sheets. To ensure the quality of the meta-analysis, all eligible publications were reviewed by 2 researchers independently according to the standardized approach and later cross checked the work of each other. The final selection of a study for inclusion in the meta-analysis was reached in consensus.

### 2.4. Statistical analyses

Random effects meta-analyses were performed with STATA 12.0 (Stata Inc. Texas) to achieve overall effect sizes of the prevalence of AR in OSA and SDB patients and to achieve a summary estimate of the odds ratio of the prevalence of AR between OSA/SDB and non-OSA/SDB patients observed in the individual




Figure 1. Flowchart of study screening and selection process.

**Table 1**  
**Characteristics of the included studies.**

Study	n	Diagnosis tool	Design	Age, years	BMI	Male (%)	Country
1 Abdullah 2012	82	Questionnaire	Epidemiological study	8.7 ± 1.1	16.6 ± 7.6	68.3	Malaysia
2 Anuntaseree 2001	85	Questionnaire/PSG	Epidemiological study	7.36 ± 0.65		56.5	Thailand
3 Bengtsson 2014	88	Questionnaire/PSG	Clinical study	50.1 ± 11.3	26.7 ± 5.0	0.0	Sweden
4 Bhattacharjee 2010	537	PSG	Retrospective study	6.9 ± 3.8		61.4	United States, Belgium and UK
5 Bozkurt 2017	150	PSG	Clinical study	44.2 ± 11.4	29.9 ± 5.0	86.7	Turkey
6 Brouillette 2001	25	PSG	Clinical study	1 to 10		56.0	Canada
7 Canova 2004	72	PSG	Case control study	60.7 (range, 50 to 80)	32.4 ± 6.6	79.4	Switzerland
8 Chan 2014	50	PSG	Clinical study	11.1 ± 2.8 (range, 6-18)		68.0	Hong Kong, China
9 Chierakul 2007	158	PSG	Retrospective study	47.2 ± 10.6		78.5	Thailand
10 Chng 2004	606	Questionnaire	Epidemiological survey	Range, 4-7		51.5	Singapore
11 Ersu 2004	151	Questionnaire	Epidemiological survey	Range, 5-13		60.3	Turkey
12 Fabbro 2014	29	PSG	Clinical study	47.0 ± 8.9	28.4 ± 3.6	82.8	Brazil
13 Francesco 2016	135	PSG	Clinical study	6.44 ± 2.55 (Range, 3-14)	15.2 ± 2.4	61.5	Brazil
14 Gadi 2014	54	PSG	Cross-sectional study	49.3 ± 13.42	38.5 ± 12.63	58.6	Saudi Arabia
15 Gadi 2016	97	PSG	Cross-sectional study	45.3 ± 13.5	37.4 ± 15.6	61.2	Saudi Arabia
16 Gupta 2009	23	Questionnaire	Clinical study	8.3 ± 4.7		30.4	United States
17 Hellgren 2009	20	PSG	Clinical study	55 ± 16	34 ± 6	72.5	Australia
18 Huang 2016	47	PSG	Clinical study	7.84 ± 0.56	11.95 ± 0.47	63.8	China
19 Huseni 2014	145	PSG	Retrospective cross-sectional study	6.26 ± 3.1	20.4 ± 6.3	62.0	United States
20 Kim 2011	19	PSG	Clinical study	7.9 ± 2.6		70.0	Korea
21 Kim 2015	70	Questionnaire	Observational cohort study	7.7 (range, 3-16)	17.5 ± 3.0	68.6	Korea
22 Kramer 2001	90	PSG	Cohort study	Average 58.3	Average 28.9	85.9	Germany
23 Kreivi 2012	290	Questionnaire/PSG	Epidemiological study	53 ± 11.9	31.9 ± 6.4		Finland
24 Larsson 2001	1064	Questionnaire	Epidemiological study	20 to 69		50.5	Sweden
25 Lavigne 2013	55	PSG	Prospective study	46 ± 9.2	28.9 ± 5.2	61.9	Canada
26 Li 2007	14	PSG	Clinical study	12.05 ± 0.76	24.88 ± 2.68	57.1	Hong Kong, China
27 Li 2008	47	PSG	Clinical study	11 ± 1.1	23.4 ± 3.4	68.3	Hong Kong, China
28 Li 2013	161	Questionnaire/PSG	Epidemiological study	10.1 ± 1.7	18.0 ± 3.1	67.6	Hong Kong, China
29 Ma 2011	86	PSG	Retrospective study	8 ± 3.1		80.2	Hong Kong, China
30 Ni 2015	127	PSG	Clinical study	Range, 3-6			China
31 Nigro 2011	90	PSG	Clinical study	49.6 ± 15.1	29.1 ± 2.1	77.0	Argentina
32 Park 2012	112	PSG	Observational cohort study	44.1 ± 13.4 (range, 20-68)	26.0 ± 4.0	83.9	Korea
33 Ramos 2006	93	PSG	Retrospective study	5.2 ± 2.1		61.3	Portugal
34 Shao 2015	415	PSG	Retrospective study	45.7 ± 11.4	27.4 ± 3.4	87.2	China
35 Sin 2014	30	PSG	Retrospective study	13.8 ± 2.6 (range, 8-17)	38.9 ± 10.5	70.0	United States
36 Sogut 2005	39	Questionnaire/PSG	Cross-sectional study	5 ± 3		63.6	Turkey
37 Sogut 2009	41	Questionnaire	Cross-sectional study	13.51 ± 1.52 (average, 12-17)		48.7	Turkey
38 Su 2017	42	PSG	Epidemiological study	average, 6-11			China
39 Virkkula 2009	41	PSG	Clinical study	44 ± 8.9 (range, 26-62)	28.1 ± 3.5 (range, 22-37)		Finland
40 Vuorjoki 2013	142	Questionnaire	Clinical study	53.8 ± 11.8	27.6 ± 5.1	65.5	Finland
41 Vuorjoki 2014	103	Questionnaire	Retrospective study	Adults		67.0	Finland
42 Weinstock 2013	223	Questionnaire/PSG	Cross-sectional study	7.08 ± 1.42		49.6	United States
43 Wirasinghe 2010	45	Questionnaire	Clinical study	44 ± 13	27.62 ± 8.82	66.7	Sri Lanka
44 Zhang 2016	93	PSG	Clinical study	5.2 ± 1.9		82.8	China


PSG = polysomnography.

studies. The significance of differences in BMI, neck circumference, AHI, and ESS between OSA/SDB patients with and without AR were carried out by STATA 12.0 with under random effects model. Heterogeneity was quantified and evaluated by the chi-squared-based  $Q$ -test and  $I^2$  test, with  $P < .05$  and  $I^2 > 50\%$  indicating evidence of heterogeneity.

### 3. Results

Data were acquired from 44 studies [8,13-56] (6086 patients) which fulfilled the eligibility criteria (Fig. 1). Important characteristics of the included studies are presented in Table 1. Average age of adult SDB patients was  $47.97 \pm 4.00$  years and  $7.73 \pm 3.34$  years for SDB children. Proportion of males in this sample population was  $68.55 \pm 20.85\%$  in adults and  $62.09 \pm$

$12.17\%$  in children. In adult SDB and OSA patients, the prevalence of AR was  $22.8$  (95%CI, 15.0-30.6)%, and  $35.2$  (95%CI, 25.6-44.7)%, respectively (Fig. 2A). In children SDB and OSA patients, the prevalence of AR was  $40.8$  (95%CI, 24.3-57.2)% and  $45.2$  (95%CI, 25.4-65.0)%, respectively (Fig. 2B). The overall prevalence of AR (in SDB and OSA) was  $41.6$  (95%CI, 23.1-60.1)% in Asia, and  $33.5$  (95%CI, 25.3-41.6)% in other continents (Europe, Oceania, and America, Fig. S1, <http://links.lww.com/MD/C714>). Pooling analysis of odds ratios observed in the children's studies showed that the prevalence of the AR was  $2.12$  (95%CI, 1.75, 2.57;  $P < .0001$ ) times higher in SDB patients than in non-SDB patients (Fig. 3A). However, in adult studies, the prevalence of AR showed no significant difference between SDB/OSA patients and non-SDB/non-OSA patients ( $P = .082$ ;  $P = .078$ , Fig. 3B). In adults, there was no



**Figure 2.** (A) Forest graph showing the percent prevalence of AR in SDB and OSA children. (B) Forest graph showing the percent prevalence of AR in SDB and OSA adults. AR= allergic rhinitis, OSA= obstructive sleep apnea, SDB= sleep-disordered breathing.

significant difference between OSA with AR and OSA without AR in BMI (mean difference:  $-0.19$  [95%CI,  $-0.45$ – $0.07$ ];  $P=.149$ ), neck circumference (mean difference:  $0.16$  [95%CI,  $-0.11$ – $0.42$ ];  $P=.245$ ), AHI (mean difference:  $-0.52$  [95%CI,  $-1.79$ – $0.74$ ];  $P=.416$ ), or ESS (mean difference:  $0.21$  [95%CI,  $-0.15$ – $0.58$ ];  $P=.246$ , Fig. S2, <http://links.lww.com/MD/C714>).

#### 4. Discussion

Nasal obstruction had long been considered as one of the leading risk factors for the upper airway obstruction during the sleep. Further, some clinical studies had found that patients with nasal congestion caused by AR were more susceptible to disturbed sleep.<sup>[57–59]</sup> Rhinorrhea, nasal blockage, or congestion always led to stuffy nose, which were the most complained symptoms of AR patients.<sup>[60]</sup> The nasal obstruction may gradually increase, resulting in daytime fatigue, sleepiness, and performance decrements. In addition, symptoms brought by AR such as

apnea and snoring were also considered to be risk factors for sleep-disordered breathing events and contributed to the development of OSA.<sup>[61]</sup> In addition, some studies had demonstrated that several chemical mediators and inflammatory cytokines play interaction roles between AR and OSA, including histamine, cysteinyl leukotrienes (cysLTs), interleukin- $1\beta$  (IL- $1\beta$ ), and interleukin-1 (IL-1) and so on.<sup>[58,62]</sup> Given the impact of AR to OSA, it seemed logical to investigate their relationship which may help understand overlapped subjects.<sup>[62]</sup>

In this meta-analysis, we reported that the prevalence of children diagnosed with AR is 2.12 times higher in SDB patients than that of non-SDB patients. However, we did not find this tendency in adults, due to immaturity of immune system in children and the studies' bias. AR was one of the most common chronic diseases in children. Children's immune system developed around the age of 2-year old. During this time, they were more likely to acquire Type I hypersensitivity which reflecting more T helper 2 lymphocyte (Th2) and consequently immuno-





Figure 2. (Continued)

globulin E (IgE) driven response to allergen exposure.<sup>[63]</sup> Adenotonsillar hypertrophy (AH) was a common comorbidity of pediatric AR, it was reported that 92.6% of AR children also suffered AH.<sup>[61]</sup> Furthermore, AH is the main cause of OSAS for children aged 3 to 6, yet adults patients were often caused by obesity.<sup>[64]</sup> This meta-analysis showed no significant difference in the prevalence of AR in OSA and non-OSA patients (children and adults). This would lead to widely underdiagnosis of OSA in group of patients in clinical practice.<sup>[65,66]</sup> Although weight and neck circumference had been shown to be good predictors for OSA in epidemiologic studies, our study suggested that there was not enough evidence that OSA adults patients coexist AR were related to individuals' BMI, neck circumference, ESS, and AHI. Additionally, Francesco and Alvarez<sup>[24]</sup> reported that AR is not an aggravating factor regarding the severity of AHI in children. The relationship between the OSA and AR is remaining a long-

standing controversy. In traditional view, AR was considered as a potential risk factor for OSA. However, Kramer et al<sup>[33]</sup> revealed that AR did not influence sleeping parameters of OSA. They found no statistically significant difference in sleeping behavior or polysomnography (PSG) parameters between AR and non-AR patients. Recent studies had also revealed AR only had effect on symptoms, but did not affect PSG results for OSA patients nor belong to risk factors for OSA.<sup>[15,17]</sup> Similarly, a demographic study conducted in OSA children reported that allergic rhinitis did not contribute to sleep disordered breathing in Australian.<sup>[67]</sup> Intranasal corticosteroids (INCS) were generally considered as the most effective agent in relieving nasal symptoms of allergic rhinitis. Therefore, it was believed that the effectiveness of INCS in relieving nasal congestion may have a positive effect on SDB. A randomized, controlled trial of OSA children aged 6 to 18 years old demonstrated that intranasal mometasone furoate effectively



**Figure 3.** Forest graph showing the meta-analysis of odds ratios reported in individual studies with regard to the odds of prevalence of AR in SDB/OSA and non-SDB/OSA [(A) Children, (B) Adults]. AR= allergic rhinitis, OSA= obstructive sleep apnea, SDB= sleep-disordered breathing.

improved obstructive apnea hypopnea index and oxygen desaturation index.<sup>[20]</sup> Beyond that, Lavigne et al<sup>[36]</sup> found that INCS not only reduced upper airway inflammation but also improved OSA morbidity in patients with concomitant AR. A meta-analysis showed that patients receiving INCS had a better effect on decreasing the AHI; however, with limited evidences.<sup>[68]</sup> In general, continuous positive airway pressure (CPAP) was the preferred therapy for OSA, whereas, INCS did not alleviate nasal symptoms during CPAP treatment in OSA patients.<sup>[69]</sup> Hence, further research should be performed on INCS in these 2 entities.

In conclusion, patients with AR were more likely to become habitual snorers, and had increasing risk of SDB and the SDB children suffered from a higher incidence of AR. Physicians may need a comprehensive understanding of the overlapping disorders before making a reasonable therapeutic strategy.

**5. Conclusion**

This meta-analysis revealed that the prevalence of AR in adult SDB/OSA patients was 23%, and 35%, and in children SDB/OSA patients 41%, and 45%, respectively. The odds of having AR were 2.12 times higher in SDB than that of non-SDB children

patients (significantly). However, there was no significant difference between OSA patients and those who suffered AR and OSA in neck circumference simultaneously BMI, AHI, or ESS. Whether AR is a risk event of OSA need further consideration, meanwhile, patients with SDB should be cautiously focused especially accompanied with nasal symptoms.

**Author contributions**

**Conceptualization:** Yuan Cao, Qiao Li.  
**Data curation:** Yuan Cao, Liyu Zhang.  
**Formal analysis:** Yuan Cao, Ying Yang.  
**Funding acquisition:** Liyu Zhang, Sancheng Cao.  
**Writing – original draft:** Shuang Wu.  
**Writing – review & editing:** Qiao Li.  
 Qiao Li: 0000-0002-2575-7005.  
 QIAO LI orcid: 0000-0002-2575-7005.

**References**

[1] Marcus CL, Brooks LJ, Draper KA, et al. Diagnosis and management of childhood obstructive sleep apnea syndrome. *Pediatrics* 2012; 130:576–84.

- [2] Sharma SK, Ahluwalia G. Epidemiology of adult obstructive sleep apnoea syndrome in India. *Indian J Med Res* 2010;131:171–5.
- [3] Heinzer R, Vat S, Marques-Vidal P, et al. Prevalence of sleep-disordered breathing in the general population: the HypnoLaus study. *Lancet Respir Med* 2015;3:310–8.
- [4] Moreira GA, Pradella-Hallinan M. Sleepiness in children: an update. *Sleep Med Clin* 2017;12:407–13.
- [5] Carberry JC, Amatoury J, Eckert DJ. Personalized management approach for OSA. *Chest* 2018;153:744–55.
- [6] Brozek JL, Bousquet J, Agache I, et al. Allergic rhinitis and its impact on asthma (ARIA) guidelines—2016 revision. *J Allergy Clin Immunol* 2017;140:950–8.
- [7] Stewart MG. Identification and management of undiagnosed and undertreated allergic rhinitis in adults and children. *Clin Exp Allergy* 2008;38:751–60.
- [8] Ersu R, Arman AR, Save D, et al. Prevalence of snoring and symptoms of sleep-disordered breathing in primary school children in Istanbul. *Chest* 2004;126:19–24.
- [9] Lin SY, Melvin TA, Boss EF, et al. The association between allergic rhinitis and sleep-disordered breathing in children: a systematic review. *Int Forum Allergy Rhinol* 2013;3:504–9.
- [10] Muliol J, Maurer M, Bousquet J. Sleep and allergic rhinitis. *J Investig Allergol Clin Immunol* 2008;18:415–9.
- [11] Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. *J Clin Epidemiol* 2009;62:e1–34.
- [12] Chesson AL Jr, Berry RB, Pack A. Practice parameters for the use of portable monitoring devices in the investigation of suspected obstructive sleep apnea in adults. *Sleep* 2003;26:907–13.
- [13] Fadzil Abdullah AA, Jamalludin AR, Norrashidah AW, et al. Prevalence of sleep disordered breathing symptoms among Malay school children in a primary school in Malaysia. *Med J Malaysia* 2012;67:181–5.
- [14] Anuntaseree W, Rookkapan K, Kuasirikul S, et al. Snoring and obstructive sleep apnea in Thai school-age children: prevalence and predisposing factors. *Pediatr Pulmonol* 2001;32:222–7.
- [15] Bengtsson C, Jonsson L, Holmstrom M, et al. Impact of nasal obstruction on sleep quality: a community-based study of women. *Eur Arch Otorhinolaryngol* 2015;272:97–103.
- [16] Bhattacharjee R, Kheirandish-Gozal L, Spruyt K, et al. Adenotonsillectomy outcomes in treatment of obstructive sleep apnea in children: a multicenter retrospective study. *Am J Respir Crit Care Med* 2010;182:676–83.
- [17] Bozkurt B, Serife Ugur K, Karamanli H, et al. Polysomnographic findings in persistent allergic rhinitis. *Sleep Breath* 2017;21:255–61.
- [18] Brouillette RT, Manoukian JJ, Ducharme FM, et al. Efficacy of fluticasone nasal spray for pediatric obstructive sleep apnea. *J Pediatr* 2001;138:838–44.
- [19] Canova CR, Downs SH, Knoblauch A, et al. Increased prevalence of perennial allergic rhinitis in patients with obstructive sleep apnea. *Respiration* 2004;71:138–43.
- [20] Chan CC, Au CT, Lam HS, et al. Intranasal corticosteroids for mild childhood obstructive sleep apnea—a randomized, placebo-controlled study. *Sleep Med* 2015;16:358–63.
- [21] Chierakul N, Chaipattarapol C, Ruttanaumpawan P, et al. Comparison of clinical and polysomnographic characteristics of non-obese and obese patients with obstructive sleep apnea. *J Med Assoc Thai* 2007;90(suppl 2):48–53.
- [22] Chng SY, Goh DY, Wang XS, et al. Snoring and atopic disease: a strong association. *Pediatr Pulmonol* 2004;38:210–6.
- [23] Dal-Fabbro C, Garbuio S, D'Almeida V, et al. Mandibular advancement device and CPAP upon cardiovascular parameters in OSA. *Sleep Breath* 2014;18:749–59.
- [24] Di Francesco RC, Alvarez J. Allergic rhinitis affects the duration of rapid eye movement sleep in children with sleep-disordered breathing without sleep apnea. *Int Forum Allergy Rhinol* 2016;6:465–71.
- [25] Gadi GU, Albar MH, Fida R, et al. The frequency of allergic rhinitis among obstructive sleep apnea patients: a hospital-based, cross-sectional study. *J King Abdulaziz Univ* 2014;21:21–59.
- [26] Gadi G, Wali S, Koshak E, et al. The prevalence of allergic rhinitis and atopic markers in obstructive sleep apnea. *J Epidemiol Glob Health* 2017;7:37–44.
- [27] Gupta N, Emre U, Kearney S, et al. Allergic rhinitis and inner-city children—is there a relationship to sleep-disordered breathing? *J Allergy Clin Immunol* 2007;119:S154.
- [28] Hellgren J, Yee BJ, Dungan G, et al. Altered positional regulation of nasal patency in patients with obstructive sleep apnoea syndrome. *Eur Arch Otorhinolaryngol* 2009;266:83–7.
- [29] Huang YS, Guilleminault C, Hwang FM, et al. Inflammatory cytokines in pediatric obstructive sleep apnea. *Medicine (Baltimore)* 2016;95:e4944.
- [30] Huseini S, Gutierrez MJ, Rodriguez-Martinez CE, et al. The link between rhinitis and rapid-eye-movement sleep breathing disturbances in children with obstructive sleep apnea. *Am J Rhinol Allergy* 2014;28:e56–61.
- [31] Kim HY, Dhong HJ, Lee JK, et al. Sleep quality and effects of position on sleep apnea in East Asian children. *Auris Nasus Larynx* 2011;38:228–32.
- [32] Kim DK, Han DH. Impact of allergic rhinitis on quality of life after adenotonsillectomy for pediatric sleep-disordered breathing. *Int Forum Allergy Rhinol* 2015;5:741–6.
- [33] Kramer MF, De La Chaux R, Dreher A, et al. Allergic rhinitis does not constitute a risk factor for obstructive sleep apnea syndrome. *Acta Otolaryngol* 2001;121:494–9.
- [34] Kreivi HR, Virkkula P, Lehto JT, et al. Upper airway symptoms in primary snoring and in sleep apnea. *Acta Otolaryngol* 2012;132:510–8.
- [35] Larsson LG, Lindberg A, Franklin KA, et al. Symptoms related to obstructive sleep apnoea are common in subjects with asthma, chronic bronchitis and rhinitis in a general population. *Respir Med* 2001;95:423–9.
- [36] Lavigne F, Petrof BJ, Johnson JR, et al. Effect of topical corticosteroids on allergic airway inflammation and disease severity in obstructive sleep apnoea. *Clin Exp Allergy* 2013;43:1124–33.
- [37] Li AM, Hung E, Tsang T, et al. Induced sputum inflammatory measures correlate with disease severity in children with obstructive sleep apnoea. *Thorax* 2007;62:75–9.
- [38] Li AM, Lam HS, Chan MH, et al. Inflammatory cytokines and childhood obstructive sleep apnoea. *Ann Acad Med Singapore* 2008;37:649–54.
- [39] Li AM, Zhu Y, Au CT, et al. Natural history of primary snoring in school-aged children: a 4-year follow-up study. *Chest* 2013;143:729–35.
- [40] Liukkonen K, Virkkula P, Aronen ET, et al. All snoring is not adenoids in young children. *Int J Pediatr Otorhinolaryngol* 2008;72:879–84.
- [41] Ma AL, Lam YY, Wong SF, et al. Risk factors for post-operative complications in Chinese children with tonsillectomy and adenotomectomy for obstructive sleep apnea syndrome. *Sleep Breath* 2012;16:909–11.
- [42] Ni K, Zhao L, Wu J, et al. Th17/Treg balance in children with obstructive sleep apnea syndrome and the relationship with allergic rhinitis. *Int J Pediatr Otorhinolaryngol* 2015;79:1448–54.
- [43] Nigro CA, Dibur E, Aimaretti S, et al. Comparison of the automatic analysis versus the manual scoring from ApneaLink device for the diagnosis of obstructive sleep apnoea syndrome. *Sleep Breath* 2011;15:679–86.
- [44] Park CE, Shin SY, Lee KH, et al. The effect of allergic rhinitis on the degree of stress, fatigue and quality of life in OSA patients. *Eur Arch Otorhinolaryngol* 2012;269:2061–4.
- [45] Ramos RT, da Cunha Daltro CH, Gregorio PB, et al. OSAS in children: clinical and polysomnographic respiratory profile. *Braz J Otorhinolaryngol* 2006;72:355–61.
- [46] Shao C, Jiang JB, Wu HC, et al. Clinical assessment and polysomnographic study of sleep apnea in a Chinese population of snorers. *J Zhejiang Univ Sci B* 2015;16:215–23.
- [47] Sin S, Wootton DM, McDonough JM, et al. Anterior nasal resistance in obese children with obstructive sleep apnea syndrome. *Laryngoscope* 2014;124:2640–4.
- [48] Sogut A, Altin R, Uzun L, et al. Prevalence of obstructive sleep apnea syndrome and associated symptoms in 3–11-year-old Turkish children. *Pediatr Pulmonol* 2005;39:251–6.
- [49] Sogut A, Yilmaz O, Dinc G, et al. Prevalence of habitual snoring and symptoms of sleep-disordered breathing in adolescents. *Int J Pediatr Otorhinolaryngol* 2009;73:1769–73.
- [50] Su MS, Xu L, Xu K, et al. Association of T lymphocyte immune imbalance and IL-10 gene polymorphism with the risk of obstructive sleep apnea in children with obesity. *Sleep Breath* 2017;21:929–37.
- [51] Virkkula P, Maasilta P, Hytonen M, et al. Nasal obstruction and sleep-disordered breathing: the effect of supine body position on nasal measurements in snorers. *Acta Otolaryngol* 2003;123:648–54.
- [52] Vuorjoki-Ranta T-R, Lobbezoo F, Tuomilehto H, et al. Mandibular advancement devices in the treatment of obstructive sleep apnea and snoring in community dental care: A pilot study on self-reported sleep quality. *Health* 2013;5:1–5.
- [53] Vuorjoki-Ranta T-R, Lobbezoo F, Tuomilehto H, et al. Mandibular advancement device therapy in obstructive sleep apnea and snoring in

- community dental care: two-year follow-up study on self-reported sleep quality, side effects, and compliance. *J Sleep Disorders Ther* 2014;3:180.
- [54] Weinstock TG, Rosen CL, Marcus CL, et al. Predictors of obstructive sleep apnea severity in adenotonsillectomy candidates. *Sleep* 2014;37:261–9.
- [55] Wirasinghe C, Godevithanage S, Nakandala SC, et al. The use of overnight pulse oximetry for obstructive sleep apnoea in a resource poor setting in Sri Lanka. *J Ceylon Coll Physicians* 2011;41:61–6.
- [56] Zhang J, Zhao J, Chen M, et al. Airway resistance and allergic sensitization in children with obstructive sleep apnea hypopnea syndrome. *Pediatr Pulmonol* 2016;51:426–30.
- [57] McColley SA, Carroll JL, Curtis S, et al. High prevalence of allergic sensitization in children with habitual snoring and obstructive sleep apnea. *Chest* 1997;111:170–3.
- [58] Young T, Finn L, Kim H. Nasal obstruction as a risk factor for sleep-disordered breathing. The University of Wisconsin Sleep and Respiratory Research Group. *J Allergy Clin Immunol* 1997;99:S757–62.
- [59] Young T, Finn L, Palta M. Chronic nasal congestion at night is a risk factor for snoring in a population-based cohort study. *Arch Intern Med* 2001;161:1514–9.
- [60] Craig TJ, McCann JL, Gurevich F, et al. The correlation between allergic rhinitis and sleep disturbance. *J Allergy Clin Immunol* 2004;114:S139–45.
- [61] Said SA, McHembe MD, Chalya PL, et al. Allergic rhinitis and its associated co-morbidities at Bugando Medical Centre in Northwestern Tanzania; a prospective review of 190 cases. *BMC Ear Nose Throat Disord* 2012;12:13.
- [62] Chirakalwasan N, Ruxrungtham K. The linkage of allergic rhinitis and obstructive sleep apnea. *Asian Pac J Allergy Immunol* 2014;32:276–86.
- [63] Sih T, Mion O. Allergic rhinitis in the child and associated comorbidities. *Pediatr Allergy Immunol* 2010;21:e107–13.
- [64] Greenfeld M, Tauman R, DeRowe A, et al. Obstructive sleep apnea syndrome due to adenotonsillar hypertrophy in infants. *Int J Pediatr Otorhinolaryngol* 2003;67:1055–60.
- [65] Jennum P, Ibsen R, Kjellberg J. Morbidity and mortality in children with obstructive sleep apnoea: a controlled national study. *Thorax* 2013;68:949–54.
- [66] Kapur V, Strohl KP, Redline S, et al. Underdiagnosis of sleep apnea syndrome in U.S. communities. *Sleep Breath* 2002;6:49–54.
- [67] Tamanyan K, Walter LM, Davey MJ, et al. Risk factors for obstructive sleep apnoea in Australian children. *J Paediatr Child Health* 2016;52:512–7.
- [68] Liu HT, Lin YC, Kuan YC, et al. Intranasal corticosteroid therapy in the treatment of obstructive sleep apnea: A meta-analysis of randomized controlled trials. *Am J Rhinol Allergy* 2016;30:215–21.
- [69] Charakorn N, Hirunwiwatkul P, Chirakalwasan N, et al. The effects of topical nasal steroids on continuous positive airway pressure compliance in patients with obstructive sleep apnea: a systematic review and meta-analysis. *Sleep Breath* 2017;21:3–8.